Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927914 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy
A Phase 2 study of Mild to Moderate Diabetic Sensorimotor Polyneuropathy, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT00927914 is a Phase 2 study of Mild to Moderate Diabetic Sensorimotor Polyneuropathy that has completed, run by Eisai. The registered enrollment target is 800 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00927914, a Phase 2 study of Mild to Moderate Diabetic Sensorimotor Polyneuropathy, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of 40 mg and 80 mg ranirestat on peroneal motor nerve conduction velocity relative to placebo in subjects with mild to moderate diabetic sensorimotor polyneuropathy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ranirestat
Study Locations (1)
Maryland
- The Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927914
The ClinicalTrials.gov registry entry for NCT00927914 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild to Moderate Diabetic Sensorimotor Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00927914 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00927914 about?
NCT00927914 is a clinical study titled "Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy". The purpose of this study is to determine the effect of 40 mg and 80 mg ranirestat on peroneal motor nerve conduction velocity relative to placebo in subjects with mild to moderate diabetic sensorimotor polyneuropathy.
What is the current status of trial NCT00927914?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 800 participants. The study started on 2009-07. Estimated completion is 2013-02.
What conditions does trial NCT00927914 study?
This clinical trial studies the following conditions: Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
What interventions are being tested in trial NCT00927914?
The interventions under investigation include: Placebo (DRUG), Ranirestat (DRUG).
Who is sponsoring clinical trial NCT00927914?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00927914 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.